These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25001263)

  • 1. Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer.
    Vargas T; Moreno-Rubio J; Herranz J; Cejas P; Molina S; González-Vallinas M; Ramos R; Burgos E; Aguayo C; Custodio AB; Reglero G; Feliu J; Ramírez de Molina A
    Mol Oncol; 2014 Dec; 8(8):1469-81. PubMed ID: 25001263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients.
    Vargas T; Moreno-Rubio J; Herranz J; Cejas P; Molina S; González-Vallinas M; Mendiola M; Burgos E; Aguayo C; Custodio AB; Machado I; Ramos D; Gironella M; Espinosa-Salinas I; Ramos R; Martín-Hernández R; Risueño A; De Las Rivas J; Reglero G; Yaya R; Fernández-Martos C; Aparicio J; Maurel J; Feliu J; Ramírez de Molina A
    Oncotarget; 2015 Mar; 6(9):7348-63. PubMed ID: 25749516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes, Obesity, and the Metabolic Syndrome as Prognostic Factors in Stages I to III Colorectal Cancer Patients.
    Croft B; Reed M; Patrick C; Kovacevich N; Voutsadakis IA
    J Gastrointest Cancer; 2019 Jun; 50(2):221-229. PubMed ID: 29335847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
    Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
    PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A SMAD4-modulated gene profile predicts disease-free survival in stage II and III colorectal cancer.
    Szeglin BC; Wu C; Marco MR; Park HS; Zhang Z; Zhang B; Garcia-Aguilar J; Beauchamp RD; Chen XS; Smith JJ
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1423. PubMed ID: 34114372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
    Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
    Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.
    Heitzer E; Artl M; Filipits M; Resel M; Graf R; Weißenbacher B; Lax S; Gnant M; Wrba F; Greil R; Dietze O; Hofbauer F; Böhm G; Höfler G; Samonigg H; Schaberl-Moser R; Balic M; Dandachi N
    Mod Pathol; 2014 Jun; 27(6):906-15. PubMed ID: 24309322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study on survival benefit for elderly patients with resected stage II or III colorectal cancer based on traditional Chinese medicine syndrome differentiation and treatment].
    Tao L; Zhu YJ; Lu XM; Gu Y; Zhao AG; Zheng J; Fu CG; Yang JK
    Zhong Xi Yi Jie He Xue Bao; 2010 Dec; 8(12):1159-64. PubMed ID: 21144459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromatin organisation and cancer prognosis: a pan-cancer study.
    Kleppe A; Albregtsen F; Vlatkovic L; Pradhan M; Nielsen B; Hveem TS; Askautrud HA; Kristensen GB; Nesbakken A; Trovik J; Wæhre H; Tomlinson I; Shepherd NA; Novelli M; Kerr DJ; Danielsen HE
    Lancet Oncol; 2018 Mar; 19(3):356-369. PubMed ID: 29402700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
    Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
    BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
    Gal R; Sadikov E; Sulkes J; Klein B; Koren R
    Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients.
    Lanza G; Gafà R; Santini A; Maestri I; Guerzoni L; Cavazzini L
    J Clin Oncol; 2006 May; 24(15):2359-67. PubMed ID: 16710035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.
    Shigeta K; Ishii Y; Hasegawa H; Okabayashi K; Kitagawa Y
    World J Surg; 2014 Dec; 38(12):3248-56. PubMed ID: 25167895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
    Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
    BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy.
    Mini E; Lapucci A; Perrone G; D'Aurizio R; Napoli C; Brugia M; Landini I; Tassi R; Picariello L; Simi L; Mancini I; Messerini L; Magi A; Pinzani P; Mazzei T; Tonelli F; Nobili S
    Int J Cancer; 2019 Nov; 145(9):2580-2593. PubMed ID: 30973654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of multiple metabolic genes in predicting the overall survival of colorectal cancer: A study based on TCGA and GEO databases.
    Shi W; Li X; Su X; Wen H; Chen T; Wu H; Liu M
    PLoS One; 2021; 16(8):e0251323. PubMed ID: 34398900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.